To investigate the antitumor effects of dendrobine on ATC cells and its mechanism targeting the JAK-STAT3 pathway.
Key Findings:
Dendrobine reduced the viability of CAL-62 and 8505C cells, with significant inhibition at 5 μM (P < 0.001).
Dendrobine treatment suppressed cell proliferation (P < 0.05) and colony formation (P < 0.001) while increasing apoptosis (P < 0.01).
Dendrobine inhibited migration and invasion (P < 0.05) and modulated epithelial-mesenchymal transition markers (E-cad upregulated, N-cad and Vim downregulated).
Dendrobine suppressed phosphorylation of JAK1, JAK2, and STAT3 (P < 0.05).
IL-6 pretreatment reversed dendrobine's effects (P < 0.001), while STAT3-siRNA enhanced its inhibitory effects (P < 0.05).
In vivo, dendrobine reduced tumor volume and weight (P < 0.001) and improved liver function indices (P < 0.05).
Interpretation:
Dendrobine exerts antitumor effects in ATC by targeting the JAK-STAT3 pathway.
Limitations:
The study primarily focuses on in vitro and in vivo models, which may not fully replicate human responses.
Further studies are needed to explore the long-term effects and safety of dendrobine in clinical settings.
Conclusion:
Dendrobine shows potential as a therapeutic candidate for ATC by modulating the JAK-STAT3 signaling pathway.
At the ASCO annual meeting, Dana-Farber’s Brian Wolpin, MD, MPH, presented positive results from the RASolute 302 trial showing a substantial prolongation of survival for patients with previously treated metastatic pancreatic cancer, regardless of RAS mutation status, taking daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor, compared with chemotherapy.
